NEW YORK, April 03, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of CarMax, Inc. (NYSE:KMX), Cameco Corporation (NYSE:CCJ), American Renal Associates Holdings, Inc (NYSE:ARA), Donaldson Company, Inc. (NYSE:DCI), Epizyme, Inc. (NASDAQ:EPZM), and Tredegar Corporation (NYSE:TG), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
KMX DOWNLOAD: http://Capital-Review.com/register/?so=KMX
CCJ DOWNLOAD: http://Capital-Review.com/register/?so=CCJ
ARA DOWNLOAD: http://Capital-Review.com/register/?so=ARA
DCI DOWNLOAD: http://Capital-Review.com/register/?so=DCI
EPZM DOWNLOAD: http://Capital-Review.com/register/?so=EPZM
TG DOWNLOAD: http://Capital-Review.com/register/?so=TG
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Capital Review, available for free download at the links above, examine CarMax, Inc. (NYSE:KMX), Cameco Corporation (NYSE:CCJ), American Renal Associates Holdings, Inc (NYSE:ARA), Donaldson Company, Inc. (NYSE:DCI), Epizyme, Inc. (NASDAQ:EPZM), and Tredegar Corporation (NYSE:TG) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
CARMAX, INC. (KMX) REPORT OVERVIEW
CarMax's Recent Financial Performance
For the three months ended November 30th, 2018 vs November 30th, 2017, CarMax reported revenue of $4,295.87MM vs $4,107.02MM (up 4.60%) and analysts estimated basic earnings per share $1.09 vs $0.82 (up 32.93%). For the twelve months ended February 28th, 2018 vs February 28th, 2017, CarMax reported revenue of $17,120.21MM vs $15,875.12MM (up 7.84%) and analysts estimated basic earnings per share $3.64 vs $3.29 (up 10.64%). Analysts expect earnings to be released on June 28th, 2019. The report will be for the fiscal period ending May 31st, 2019. The reported EPS for the same quarter last year was $1.33. The estimated EPS forecast for the next fiscal year is $5.48 and is expected to report on April 3rd, 2020.
To read the full CarMax, Inc. (KMX) report, download it here: http://Capital-Review.com/register/?so=KMX
-----------------------------------------
CAMECO CORPORATION (CCJ) REPORT OVERVIEW
Cameco's Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Cameco reported revenue of $634.53MM vs $630.43MM (up 0.65%) and analysts estimated basic earnings per share $0.31 vs -$0.12. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Cameco reported revenue of $1,613.72MM vs $1,663.80MM (down 3.01%) and analysts estimated basic earnings per share $0.32 vs -$0.40. Analysts expect earnings to be released on April 26th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $0.05. The estimated EPS forecast for the next fiscal year is -$0.12 and is expected to report on February 14th, 2020.
To read the full Cameco Corporation (CCJ) report, download it here: http://Capital-Review.com/register/?so=CCJ
-----------------------------------------
AMERICAN RENAL ASSOCIATES HOLDINGS, INC (ARA) REPORT OVERVIEW
American Renal Associates' Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, American Renal Associates reported revenue of $211.02MM vs $187.71MM (up 12.42%) and analysts estimated basic earnings per share $0.06 vs $0.26 (down 76.92%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, American Renal Associates reported revenue of $745.11MM vs $749.77MM (down 0.62%) and analysts estimated basic earnings per share -$0.24 vs -$0.28. Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $0.11. The estimated EPS forecast for the next fiscal year is $0.54 and is expected to report on April 2nd, 2019.
To read the full American Renal Associates Holdings, Inc (ARA) report, download it here: http://Capital-Review.com/register/?so=ARA
-----------------------------------------
DONALDSON COMPANY, INC. (DCI) REPORT OVERVIEW
Donaldson's Recent Financial Performance
For the three months ended January 31st, 2019 vs January 31st, 2018, Donaldson reported revenue of $703.70MM vs $664.70MM (up 5.87%) and basic earnings per share $0.47 vs -$0.40. For the twelve months ended July 31st, 2018 vs July 31st, 2017, Donaldson reported revenue of $2,734.20MM vs $2,371.90MM (up 15.27%) and analysts estimated basic earnings per share $1.38 vs $1.76 (down 21.59%). Analysts expect earnings to be released on May 30th, 2019. The report will be for the fiscal period ending April 30th, 2019. The reported EPS for the same quarter last year was $0.53. The estimated EPS forecast for the next fiscal year is $2.54 and is expected to report on September 5th, 2019.
To read the full Donaldson Company, Inc. (DCI) report, download it here: http://Capital-Review.com/register/?so=DCI
-----------------------------------------
EPIZYME, INC. (EPZM) REPORT OVERVIEW
Epizyme's Recent Financial Performance
For the twelve months ended December 31st, 2018 vs December 31st, 2017, Epizyme reported revenue of $21.70MM vs $10.00MM (up 117.00%) and analysts estimated basic earnings per share -$1.72 vs -$2.18. Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.49. The estimated EPS forecast for the next fiscal year is -$1.94 and is expected to report on February 25th, 2020.
To read the full Epizyme, Inc. (EPZM) report, download it here: http://Capital-Review.com/register/?so=EPZM
-----------------------------------------
TREDEGAR CORPORATION (TG) REPORT OVERVIEW
Tredegar's Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Tredegar reported revenue of $294.63MM vs $259.49MM (up 13.54%) and analysts estimated basic earnings per share $0.78 vs -$0.54. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Tredegar reported revenue of $1,095.93MM vs $1,013.04MM (up 8.18%) and analysts estimated basic earnings per share $0.75 vs $1.16 (down 35.34%). Analysts expect earnings to be released on May 7th, 2019. The report will be for the fiscal period ending March 31st, 2019.
To read the full Tredegar Corporation (TG) report, download it here: http://Capital-Review.com/register/?so=TG
-----------------------------------------
ABOUT CAPITAL REVIEW
Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.
REGISTERED MEMBER STATUS
Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Morena Zambada, Media Department
Office: +1 (410) 280-7496
E-mail: media@Capital-Review.com
© 2019 Capital Review. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Capital-Review.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.